Bristol Myers Squibb (BMY) Cost of Revenue (2009 - 2026)

Bristol Myers Squibb has disclosed Cost of Revenue across 18 years of filings, most recently posting $3.4 billion for Q1 2026.

• In Q1 2026, Cost of Revenue rose 12.79% year-over-year to $3.4 billion; the TTM figure through Mar 2026 stood at $14.3 billion (up 1.82% YoY), while the FY2025 annual figure was $13.9 billion, changed 0.23% from the prior year.
• Cost of Revenue eased to $3.4 billion in Q1 2026, from $4.1 billion in the prior quarter.
• Over the last five years, Cost of Revenue for BMY reached as high as $4.8 billion in Q4 2024 and fell as low as $2.4 billion in Q3 2022.
• The 5-year median for Cost of Revenue is $2.9 billion (2024), against an average of $3.1 billion.
• Annual changes were most pronounced in 2024 — Cost of Revenue soared 75.3% — and 2025, when it fell 14.86%.
• A 5-year view of Cost of Revenue shows it stood at $2.6 billion in 2022, then grew by 5.86% to $2.7 billion in 2023, then soared by 75.3% to $4.8 billion in 2024, then dropped by 14.86% to $4.1 billion in 2025, then declined by 16.5% to $3.4 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.4 billion, $4.1 billion, and $3.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.